Yield10 Bioscience Inc
NASDAQ:YTEN
Yield10 Bioscience Inc
NASDAQ:YTEN
Price:
2.236 USD
-5.65%
Market Closed
Updated:
May 17, 2024
Yield10 Bioscience Inc
Accrued Liabilities
|
Yield10 Bioscience Inc
Accrued Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
Accrued Liabilities
$2.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
34%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Yield10 Bioscience Inc's Accrued Liabilities?
Accrued Liabilities
2.7m
USD
2.7m
USD
Based on the financial report for Dec 31, 2023, Yield10 Bioscience Inc's Accrued Liabilities amounts to 2.7m USD.
What is Yield10 Bioscience Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-6%
-6%
Over the last year, the Accrued Liabilities growth was 79%. The average annual Accrued Liabilities growth rates for Yield10 Bioscience Inc have been 14% over the past three years , 12% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
